[HTML][HTML] Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto, OA O'Connor… - BMC cancer, 2021 - Springer
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
[HTML][HTML] Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto, OA O'Connor… - BMC Cancer, 2021 - ncbi.nlm.nih.gov
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
K Oiwa, N Hosono, R Nishi, L Scotto, OA O'Connor… - BMC Cancer, 2021 - go.gale.com
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
[HTML][HTML] Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto… - BMC …, 2021 - bmccancer.biomedcentral.com
Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with
relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance …
relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto, OA O'Connor… - BMC Cancer, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with …
Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
K Oiwa, N Hosono, R Nishi, L Scotto, OA O'Connor… - BMC Cancer, 2021 - europepmc.org
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto… - BMC …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
K Oiwa, N Hosono, R Nishi, L Scotto… - BMC …, 2021 - search.proquest.com
Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …
[DOC][DOC] Characterization of Newly Established Pralatrexate-resistant Cell Lines and the Mechanisms of Resistance
K Oiwa, N Hosono, R Nishi, L Scott, OA O'Connor… - assets.researchsquare.com
Background: Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma. However, some patients exhibit intrinsic …
with relapsed/refractory peripheral T-cell lymphoma. However, some patients exhibit intrinsic …
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
K Oiwa, N Hosono, R Nishi, L Scotto… - BMC …, 2021 - search.ebscohost.com
Abstract < bold> Background: </bold> Pralatrexate (PDX) is a novel antifolate
approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma …
approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma …